- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 394.2M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GRND | RCKT |
|---|---|---|
| Price | $15.95 | $2.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $18.80 | ★ $29.73 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.11 | 26.37 |
| EPS | 0.24 | ★ 0.66 |
| Revenue | ★ $439,898,000.00 | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $17.04 | $64.28 |
| P/E Ratio | $66.13 | ★ $4.08 |
| Revenue Growth | ★ 27.64 | N/A |
| 52 Week Low | $9.79 | $2.53 |
| 52 Week High | $18.50 | $5.45 |
Technical Indicators
Market Signals| Indicator | GRND | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 27.59 |
| Support Level | $15.05 | N/A |
| Resistance Level | $16.10 | $3.67 |
| Average True Range (ATR) | 0.51 | 0.23 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 77.91 | 3.71 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discrete and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.